Access to Cancer Medicines Coalition calls for patient safeguarding during Brexit

Tackle Prostate Cancer has joined forces with other national cancer charities and patient representative organisations in calling for the interests of people affected by cancer to be safeguarded throughout the second phase of Brexit negotiations.

In a letter to Jeremy Hunt MP, Health Secretary and Greg Clark MP, Business Secretary, the Access to Cancer Medicines Coalition has warned that we must ensure the UK retains prompt access to the most innovative cancer treatments and the ability to collaborate on the development of new drugs through clinical trials.

The Coalition stated to Ministers that EU-UK regulatory alignment is critical if we are serious about improving outcomes for people affected by cancer in the UK.

Yesterday, Brexit negotiators negotiators Michel Barnier and David Davis agreed on a “large part” of the agreement that will lead to the “orderly withdrawal” of the UK. Tackle Prostate Cancer and the Access to Cancer Medicines Coalition will continue to raise awareness of these issues, ensuring prostate cancer patients and their families do not fall between the cracks of any transitional period agreements.


About the Access to Cancer Medicines Coalition

The Access to Cancer Medicines Coalition (ACMC) brings together 24 cancer charities and patient representative organisations. Its aim is to ensure that cancer patients have timely access to the most clinically effective medicines for their condition on the NHS, and using our combined knowledge, experience and contact with people affected by cancer we will ensure that the patient voice is strongly heard in both public conversations and official decision-making relating to access.

Share

You might also like...

Skip to content